Drug intelligence / Profile preview

collagenase clostridium histolyticum-aaes + antifibrinolytic agent

Development stage
Unknown
Lead developer
Mallinckrodt
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Subcutaneous, Oral, Intravenous
01

Overview

Collagenase clostridium histolyticum-aaes + antifibrinolytic agent is a theoretical combination of two pharmacological agents: collagenase clostridium histolyticum-aaes, a purified bacterial enzyme preparation used for the enzymatic disruption of collagen, and a drug from the antifibrinolytic class, which inhibits fibrinolysis (the breakdown of fibrin blood clots). Collagenase clostridium histolyticum-aaes (marketed as Qwo, developed by Endo Aesthetics) is indicated for injection to treat moderate to severe cellulite in the buttocks of adult women by disrupting fibrous collagen septae under the skin, resulting in a skin-smoothing effect. Antifibrinolytic agents (such as tranexamic acid, aminocaproic acid) help reduce or prevent excessive bleeding by inhibiting the activation of plasminogen to plasmin, thereby stabilizing fibrin clots. The combination might be considered to prevent excessive bruising or bleeding at injection sites, but no specific approved product by this exact combination name is currently marketed or described in literature[1][2][3][4][5][6][7].

02

Targets

COL1 (Collagen type I)COL4 (Collagen IV)PLG (Plasminogen)

Beyond the preview

Go deeper on collagenase clostridium histolyticum-aaes + antifibrinolytic agent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on collagenase clostridium histolyticum-aaes + antifibrinolytic agent.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call